Health Care & Life Sciences » Biotechnology | Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.36
Market Cap
$2.52 B
Shares Outstanding
145.51 M
Public Float
129.63 M

Profile

Address
11388 Sorrento Valley Road
San Diego California 92121
United States
Employees -
Website http://www.halozyme.com
Updated 07/08/2019
Halozyme Therapeutics, Inc. is a biopharmaceutical company specializes in research, development, and commercialization of human enzymes and other drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.

Financials

View All
Created with Highcharts 5.0.14Halozyme Therapeutics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.83 47883 47868 37568 37532 23132 231103 023103 02362 97162 97180 33080 330201320142015201620172018025k50k75k100k125k
Created with Highcharts 5.0.14Halozyme Therapeutics Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.54 79954 79975 33475 334135 057135 057146 691146 691316 613316 613151 862151 8622013201420152016201720180100k200k300k400k

Helen I. Torley
President, Chief Executive Officer & Director
Bernadette M. Connaughton
Director